Kornimate/medical-research-clean huggingface dataset:
performance characteristics and technical outcomes of single-use vs. reusable gastroscopes evaluated in the or

Conditions: Upper Gastrointestinal Disorder

Summary: the goal of this clinical trial is to investigate whether single-use gastroscopes are as good as reusable gastroscopes when used in the operation theater in all patients where gastroscopy in the operation theater is indicated. the main question it aims to answer is: - is the technical success and performance characteristics the same for single-use and reusable gastroscopies? researchers will compare single-use gastroscopes with reusable gastroscopes to see if the technical success and performance characteristics are the same in the to groups. participants will in the first period have gastroscopy with a single-use gastroscope. in the second period participants will have gastroscopy with a reusable gastroscope.


Eligibility criteria:
inclusion criteria: * acute, subacute or elective gastroscopies in the operating theater * age ≥ 18 years exclusion criteria: * none

Keywords: gastroscopy upper endoscopy gastroscope single-use reusable
different immunochemotherapies in small b-cell non-hodgkin lymphoma (inhl)

Conditions: Lymphoma, Non-Hodgkin

Summary: describe the application status of different immunochemotherapies in small b-cell non-hodgkin lymphoma (inhl), observe the therapeutic efficacy and safety of the treatment modalities.

evaluated the efficacy and safety of different immunochemotherapies in small b-cell non-hodgkin lymphoma (inhl)

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * initial or first recurrent inhl confirmed by histopathology, including fl (1-3a), mzl, mcl; * sign an informed consent form; * researchers evaluate patients who can benefit from receiving immunochemotherapy. exclusion criteria: * there are contraindications to any medication in the treatment plan; * pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication; * researchers believe that patients who are not suitable for enrollment.
modulation of lactase expression by a new ppargamma ligand in duodenal biopsies

Conditions: Lactose Intolerance

Summary: this study is designed to assess the effect of a new ppargamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. based on their previous experimental results, the investigators hypothesized that modulating intestinal ppargamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut


Eligibility criteria:
inclusion criteria: * subjects undergoing gastroduodenal endoscopy for digestive cancer screening * subjects undergoing gastroduodenal endoscopy for ulcerative gastroduodenal diseases * subjects undergoing gastroduodenal endoscopy for epigastric pains * subjects undergoing gastroduodenal endoscopy for gastroesophageal reflux diseases exclusion criteria: * subjects with macroscopic duodenal lesions detected at endoscopy * subjects suffering from coeliac disease * subjects suffering from atrophic gastritis * subjects who use anticoagulant * pregnancy or breast feeding

Keywords: ppargamma lactose intolerance lactase
dietary control alone versus dietary control plus use of proton pump inhibitors to treat pediatric hoarseness

Conditions: Dysphonia

Summary: this study will examine whether lansoprazole (prevacid) and dietary control versus dietary control alone will improve pediatric hoarseness symptoms.


Eligibility criteria:
inclusion criteria: 1. healthy children with a diagnosis of dysphonia age 3-18 years. 2. dysphonia must be present for at least one month duration. 3. may have vocal cord nodules present. 4. pre-enrollment flexible fiberoptic laryngoscopy must not show any potentially life-threatening cause, including but not limited to laryngeal papillomatosis, congenital glottic webs, vocal cord paralysis, or benign and malignant neoplasms. 5. must be able to cooperate with recording of voice for analysis(3 seconds of sustained vowel). 6. caregiver must be able to read, write, and understand english. 7. patient with history of diagnosed asthma must have their asthma well controlled and treated at the time of enrollment for study. exclusion criteria: 1. dysphonia must not be due to a potentially life-threatening cause, such as laryngeal papillomatosis, congenital glottic webs, vocal cord paralysis, or benign and malignant neoplasms. this will be determined by visualization with flexible fiberoptic laryngoscopy. 2. dysphonia must not be due to an acute upper respiratory infection. 3. must not have been treated with proton pump inhibitor medication in the past 12 months. 4. inability of child to cooperate with recording of voice for analysis. 5. inability of caregiver to read, write, and understand english. 6. mental retardation, cognitive impairment, or developmental delay. 7. history of allergic reaction of any kind to lansoprazole or any other proton pump inhibitor.

Keywords: horseness
mediterranean diet as an add-on therapy for induction of remission in patients with active crohn's disease

Conditions: Crohn's Disease

Summary: this clinical study is designed to evaluate the effect of mediterranean diet as an add-on therapy for induction of remission in adult patients with active crohn's disease and to evaluate its effects on clinical, inflammatory and microbial parameters.

the mediterranean diet has been associated with anti-inflammatory properties and with decreased risk for several chronic diseases. however, the effect of mediterranean diet has not been evaluated in patients with inflammatory bowel diseases. the purpose of this study is to determine whether mediterranean diet is superior to a low residue diet as an add-on therapy for induction of remission in adult patients with active crohn's disease and to evaluate its effects on clinical, inflammatory and microbial parameters. seventy eligible patients will be randomly assigned to one of two dietary interventions: mediterranean diet or low residue diet, as an add-on therapy for induction of remission of active crohn's disease. the effect of the dietary regimens on clinical, inflammatory and microbial parameters will be assessed at 8 and 52 weeks.

Eligibility criteria:
inclusion criteria: * males and females * age: 18-75 * diagnosis of crohn's disease * montreal classification- b1 * cdai: 150-450 + crp\>0.5 or fecal calprotectin \>200 * induction therapy with corticosteroids, 5-asa, aza, 6-mp, mtx or biologic therapy * capacity to give informed consent exclusion criteria: * ileostomy or colostomy * exclusive enteral nutrition/ partial enteral nutrition * history of or current severe systemic diseases * history of admission due to bowel obstruction * positive clostridium difficile toxin * positive salmonella, shigella, campylobacter, stool culture * pregnancy or lactation * use of antibiotics or steroids one month prior to inclusion

Keywords: crohn's disease inflammatory bowel diseases mediterranean diet microbiome
autologous plasmin and fibrinolytic system in diabetic retinopathy

Conditions: Macular Edema

Summary: the purpose of this study is to evaluate in a prospective study the efficacy of intravitreal autologous plasmin enzyme in macular edema and to analyze the fibrinolytic system in vitreous body.

autologous plasmin enzyme has been used to liquefy the gel structure of the vitreous body and to decrease the adherence of the posterior vitreous cortex to the inner limiting membrane in clinical studies. the investigators performed intravitreal autologous plasmin enzyme for macular edema. in addition, the investigators collected vitreous body in macular edema and analyzed fibrinolytic system.

Eligibility criteria:
inclusion criteria: * eyes with macular edema * those who showed poor outcomes in visual acuity or macular thickness after grid laser,triamcinolone,or bevacizumab therapy or a combination of these treatments. exclusion criteria: * uncontrolled blood pressure (systolic and diastolic blood pressure greater than 150 and 90 mm hg, respectively) * renal insufficiency * intraocular surgery or any intravitreal treatment during the previous 3 months * history of ocular hypertension and/or glaucoma

Keywords: autologous plasmin macular edema vitreous
comparison of two physical activity interventions in individuals with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study will examine the effectiveness of aquatic therapy on a range of ms-related symptoms such as cognition, mood, fatigue and quality of life (qol).

aim 1. examine the impact of aquatic exercise on cognitive abilities. the proposed study will test the hypotheses that, compared to the wait-list control group, the treatment group will demonstrate significantly greater improvements in cognitive outcomes, specifically: processing speed, executive functioning, working memory and long-term memory. aim 2. the current study will examine the impact of an aquatic exercise on fatigue, mood, wellness, qol and physical functioning. specifically the investigators predict that aquatic exercise will lead to improvements in: 1.fatigue 2. health related qol 3. depression/anxiety 4. self-efficacy 5. physical functioning (i.e. gait and walking). aim 3: examine the long-term effects of aquatic exercise on all outcome measures.

Eligibility criteria:
inclusion criteria: * diagnosis of ms. * between the ages of 18-65. * read and speak english fluently. exclusion criteria: * history of significant substance abuse. * history of neurological disease other than ms (for example, stroke, epilepsy, or brain injury). * history of significant psychiatric illness (for example, bipolar disorder or schizophrenia). * has engaged in more than 30 minutes of moderate to strenuous exercise per week during the past six months.
physiotherapist led triage in primary care for patients with hip or knee oa

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the overall aim with the study is to evaluate physiotherapist led triage in primary care compared to usual care (assessment by an orthopaedic surgeon in an orthopaedic department) for patients with hip or knee osteoarthritis referred for orthopaedic consultation.

the primary aim of the study is to evaluate if there is any difference in perceived quality of care using the item "i received the best possible examination and treatment (as far as i can tell)" between physiotherapist led (pt led) triage in primary care compared to usual care (assessment by an orthopaedic surgeon (os) in an orthopaedic department) for patients with hip or knee osteoarthritis (oa) referred for orthopaedic consultation. furthermore, to evaluate whether there is any difference in 2) perceived quality of care as a whole, 3) management outcome and hip/knee replacement surgery conversion rate, 4) patient reported outcome measures such as health related quality, pain and function in short and long term and 5) costs between the two care models.

Eligibility criteria:
patients with hip or knee oa assessed by a gp at any of the included health care centers in the study, and referred on for orthopaedic consultation to any of the included hospitals in the västra götaland. inclusion criteria: * primary oa in hip or knee * understands and speak swedish exclusion criteria (if stated in the referral) * previously been assessed for the same condition by an orthopaedic surgeon * referred by an orthopaedic surgeon * secondary oa due to fractures or osteonecrosis of the femoral head * referral to a specific orthopaedic surgeon

Keywords: physiotherapist orthopaedic triage quality of care surgery conversion rate
ak112 in combination with chemotherapy in advanced squamous non-small cell lung cancer

Conditions: Advanced Squamous Non Small Cell Lung Cancer

Summary: this trial is a phase iii study. all patients are stage iiib/c (unsuitable for radical therapy) or stage iv squamous non-small cell lung cancer(nsclc), eastern cooperative oncology group (ecog) performance status 0-1. the purpose of this study is to evaluate the efficacy and safety of ak112 combined with chemotherapy versus tislelizumab combined with chemotherapy in patients with advanced squamous nsclc.


Eligibility criteria:
inclusion criteria: * be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). * ≥18 years old and ≤75 years old (at the time consent is obtained). * has an eastern cooperative oncology group (ecog) performance status of 0 or 1. * has a life expectancy of at least 3 months. * has a histologically confirmed diagnosis of squamous nsclc. * has stage iiib/c or iv nsclc (american joint committee on cancer \[ajcc\]). * has no prior systemic anti-tumor therapy for locally advanced or metastatic nsclc. * has measurable disease based on response evaluation criteria in solid tumors (recist) 1.1. * has adequate organ function. exclusion criteria: * histological diagnosis of non-squamous nsclc. * has egfr-sensitive mutations or alk gene translocations. * known ros1 rearrangement, met exon 14 skipping mutation, or ret gene fusion positivite. * is currently participating in a study of an investigational agent or using an investigational device. * has a diagnosis of immunodeficiency or is receiving systemic steroid therapy within 2 years prior to the first dose of study treatment. * has undergone major surgery within 30 days of study day 1. * has known active central nervous system (cns) metastases. * has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). * has an active infection requiring systemic therapy. * has known active hepatitis b (e.g., hbsag reactive) or hepatitis c (e.g., hcv rna \[qualitative\] is detected). * history of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment. * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study. * has received a live virus vaccine within 30 days of the planned first dose of study therapy. * has any concurrent medical condition that, in the opinion of the investigator, would complicate or compromise compliance with the study or the well-being of the subject.
developing an opioid taper intervention before total joint arthroplasty

Conditions: Arthritis Knee; Arthritis Hip; Chronic Pain

Summary: the goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. the main questions it aims to answer are: * is the intervention feasible and acceptable to patients? * does the intervention result in a decrease in opioid dose during the preoperative period? participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. the pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.


Eligibility criteria:
inclusion criteria: * decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks * currently taking between 20 and 90 mme of oral opioids, and that dose has been stable for at least 3 months * have a reliable telephone number for contact * speaks english exclusion criteria: * taking opioid medications that include: * buprenorphine * methadone * long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine) * transdermal formations of opioid pain medications (e.g., fentanyl patches)

Keywords: opioids
jasp-1 for children recently diagnosed and their parents

Conditions: JIA; Support Program; Patient Satisfaction; Patient Outcome Assessment

Summary: to implement and evaluate a patient-and family-centered juvenile arthritis support program during one year (jasp-1) for children recently diagnosed with jia and their parents and after 12 months compare satistaction with care and health outcomes with a control group receiving standard care.

children diagnosed with jia (n=50) and their parents were offered the opportunity to participate in the jasp-1 from the time of diagnosis and the following year. one year after the jia diagnosis, the children and/or their parents were invited to answer a study-specific questionnaire comprising 16 questions. the questionnaire assessed their experiences with the information, communication, participation, and emotional support they had received during the first year with jia. in order to compare outcomes, the questionnaire was answered by both participants in jasp-1 and patients and parents receiving standard care (n=25). one example of a question is; if you asked questions to the health care professionals, did you get answers that you understood? response alternatives range from "no, not at all" to "yes, completely" ona 5-point likert scale. in swedish pediatric rheumatology quality register (pedsrq) information about treatment, disease- and joint activity (registered by medical doctor), and patient reported outcome measures (prom), are measured. the total child health activity questionnaire (chaq-score), as well as active joints and treatment at 12 months was registered in the pedsrq and analyzed. the study specific questionnaire measuring patient satisfaction has been developed in collaboration with the swedish municipalities and county councils. experimental and descriptive analyses will be performed using software for statistical analysis, spss. distributions of responses will be calculated in percentage. differences in proportions between groups will be determined by performing chi-square tests.

Eligibility criteria:
inclusion criteria: * children 1-16 years old * diagnosed with jia at their first visit to the prc exclusion criteria: * children that did not fulfil the criteria for jia * children/parents who could not understand the swedish language.

Keywords: jia support program patient satisfaction patient outcome assessment
multifactorial approach to emergent cerclage

Conditions: Cervical Insufficiency

Summary: though cervical insufficiency is a common cause of second trimester pregnancy loss, the placement of an emergent cerclage in these patients is thought to improve perinatal outcomes. it is unknown whether the use of tocolytics and antibiotics prolongs pregnancies complicated by need for emergent cerclage. the objective is to determine whether administration of peri-operative antibiotics and indomethacin to patients receiving emergent cerclages for cervical insufficiency increases latency period to delivery compared with patients receiving emergent cerclage alone.


Eligibility criteria:
inclusion criteria: * ga 16+0 to 23+6 weeks * singleton gestation * presence of cervical dilation as diagnosed on digital examination * intact membranes exclusion criteria: * age \<18 years * allergy to nsaids * renal disease * allergy to penicillins and clindamycin * currently on antibiotics or indomethacin for any reason * hiv positive * pregnancies complicated by fetal congenital anomalies * preterm premature rupture of membranes * fever of 100.4 degrees fahrenheit or higher * any patient having received a therapeutic cerclage during the current pregnancy

Keywords: cervical insufficiency
the efficacy and safety of peg-rhg-csf in neutropenia after chemotherapy

Conditions: Mammary Cancer; Lymphoma; Bone Tumour; Gynecological Tumors

Summary: the purpose of the trail is to evaluate the efficacy and safety of peg-rhg-csf in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.


Eligibility criteria:
inclusion criteria: 1. patients with age between 18 and 70 years. 2. breast cancer, lymphoma, bone tumor or gynecologic tumor patients. 3. with multi-cycle chemotherapy. 4. with iii/iv degree neutropenia after the last cycle of chemotherapy and plans to use the same regimen in the subsequent cycles.fn risk of the chemotherapy regimens is ≥20%，or 10%≤fn risk\<20% and has high risk factors associated with fn. 5. kps score≥ 70. 6. expected to survive more than 3 months. 7. no hematologic system disease and anc≥1.5×10e9/l, pkt≥80×10e9/l, hb≥ 75g/l, wbc≥3×10e9/l, and no bleeding tendency. 8. written informed consent are acquired. - exclusion criteria: 1. with infection or systemic antibiotic therapy 72h before chemotherapy. 2. with any abnormal hematopoietic function. 3. received transplantation within 3 months. 4. suffered from other malignant tumor or brain metastases. 5. tbil, alt,ast \> 2.5×uln; if it were caused by liver metastases, tbil, alt,ast \>5×uln. 6. cr \>1.5 ×uln. 7. sensitive to the product or other genetically engineered biological products from escherichia coli strains. 8. mental or nervous system disorders. 9. refused to accept contraceptive measures. 10. other situations that investigators consider as contra-indication for this study. -
exercise and severe depression: clinical and biological analysis

Conditions: Depression

Summary: the study aimed to evaluate the use of exercise as a complementary strategy to treat severe major depression in inpatients. hypothesis: exercise can be used as a safe and efficacious complimentary strategy in severe depressed inpatients.


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder according to m.i.n.i (dsm-iv) criteria american psychiatry association(1994) * score of 25 or more on hamilton-17 * not being involved in other physical activity programs during the hospitalization * aged between 18 and 60 years * being able to read, understand, and provide written informed consent exclusion criteria: * have three or more cardiovascular risk factors according to physical activity readiness questionnaire (par-q) * are unable to exercise due other clinical condition * have diagnosis of schizophrenia, bipolar disorder or current use of alcohol or other drugs according to m.i.n.i dsm-iv criteria american psychiatry association(1994) * if they are taking beta-blocking medications

Keywords: severe depression quality of life exercise bdnf tbars
local treatment by thermic destruction of primitive breast cancer

Conditions: Breast Cancer

Summary: demonstrate the effectiveness of laser in the treatment of cancerous lesions by determinating with histological analysis of the specimen the percentage of tumor cells remaining in the area treated by the laser


Eligibility criteria:
inclusion criteria: * noninflammatory unilateral and unifocal breast cancer * size \</= 20mm (ultrasound measure) * histological confirmation of cancer by biopsy grade status hormone and her2. * good delineation of the lesion on ultrasound. * minimum distance of 5 mm between the tumor and the skin between the tumor and muscle. * age between 18 and 80 * ecog performance status 0 or 1